Medical devices face cybersecurity risks even after being approved and released. The FDA's postmarket cybersecurity guidance focuses on managing medical device cyber risks to protect patient safety. Here's what you need to know:

  • Postmarket cybersecurity involves identifying, assessing, and addressing vulnerabilities in devices already in use.
  • The FDA's framework, built on its 2016 guidance and Section 524B of the FD&C Act (effective March 29, 2023), mandates ongoing monitoring, vulnerability disclosure policies, and timely updates.
  • Key requirements for manufacturers include maintaining a Software Bill of Materials (SBOM), setting up a Coordinated Vulnerability Disclosure (CVD) policy, and forming a dedicated Product Security Incident Response Team (PSIRT).
  • Vulnerabilities must be prioritized based on their exploitability and potential impact on patient safety, with clear timelines for patches and mitigations.
  • Manufacturers are required to notify the FDA within 10 working days if a vulnerability could prevent death or serious injury.
  • Documentation, including SBOM updates, vulnerability management logs, and clinical risk assessments, is critical for compliance during FDA inspections.

This guidance emphasizes continuous oversight, collaboration with healthcare providers, and integrating cybersecurity into quality systems to ensure medical devices remain secure throughout their lifecycle.

FDA Postmarket Cybersecurity Compliance: Key Steps for Medical Device Manufacturers

FDA Postmarket Cybersecurity Compliance: Key Steps for Medical Device Manufacturers

Webinar: Postmarket Cybersecurity Management

Vulnerability Monitoring and Intake Processes

Once a product is shipped, manufacturers need to have a clear process in place to identify vulnerabilities and take action to ensure patient safety. This aligns with the FDA's postmarket guidance.

Sources of Vulnerability Information

Staying informed about vulnerabilities requires tapping into multiple sources. Public databases such as the National Vulnerability Database (NVD) and the CISA Known Exploited Vulnerabilities (KEV) Catalog are great starting points for tracking known threats. For medical device-specific risks, resources like ICS-CERT medical advisories are invaluable [2][3][4].

Third-party vendor risk management and supplier updates are another critical source. For example, Microsoft's "Patch Tuesday" updates or notifications from Linux and Java framework maintainers provide insights into vulnerabilities in widely used proprietary components [2][4].

Manufacturers should also encourage external researchers to report vulnerabilities through a Coordinated Vulnerability Disclosure (CVD) program. Setting up a dedicated channel, such as an email like psirt@company.com, can streamline this process [3]. Additionally, healthcare organizations using these devices in real-world clinical settings often uncover issues that internal testing might miss [2].

"SBOM currency is the foundation of every other postmarket obligation - you cannot monitor what you haven't inventoried." - Christian Espinosa, CEO, Blue Goat Cyber [2]

These varied inputs provide the foundation for effective monitoring, which leads to actionable best practices.

Continuous Monitoring Best Practices

A Software Bill of Materials (SBOM) is a cornerstone of ongoing monitoring efforts. By maintaining an accurate and current SBOM, teams can filter vulnerability alerts to focus on components actually present in their devices. It's no surprise that 81% of procurement professionals now consider SBOMs essential for managing devices [3]. For those using CI/CD pipelines, automating SBOM updates with every software release eliminates the need for manual tracking [2][5].

With an up-to-date SBOM, manufacturers can quickly triage vulnerabilities as they emerge.

Another key step is forming a dedicated Product Security Incident Response Team (PSIRT). This team handles vulnerability intake, prioritization, and resolution. Without clear ownership, reports can slip through the cracks, leading to delays. Publishing a CVD policy that includes "Safe Harbor" language can also encourage researchers to report vulnerabilities without fear of legal repercussions [3].

Triage and Prioritization of Vulnerabilities

Once vulnerabilities are identified, manufacturers must prioritize them based on their potential impact. The FDA advises evaluating vulnerabilities using two main criteria: exploitability and potential patient harm [2]. The Common Vulnerability Scoring System (CVSS v4.0) provides a helpful baseline, incorporating safety impact metrics, but clinical judgment is still essential [2][6].

For example, a moderate CVSS score on a component critical to clinical performance - like a cardiac monitor's alarm system - might demand more urgent attention than a high score on a non-essential administrative module. Clinical risk always takes precedence, and the rationale behind prioritization decisions should be clearly documented [2].

Under 21 CFR Part 806, manufacturers are required to notify the FDA within 10 working days if a vulnerability correction is necessary to prevent death or serious injury [2].

CVSS Score (v4.0) Clinical Risk Level Expected Patch Timeline
9.0 – 10.0 Critical (patch within 30 days) 24–72 hours (mitigation); 30 days (patch)
7.0 – 8.9 High (significant safety concern) 30–90 days
4.0 – 6.9 Medium (moderate concern) 90–180 days
0.1 – 3.9 Low (theoretical concern) Next scheduled release

When immediate patching isn't possible, compensating controls such as network segmentation or firewall rules can help minimize risks while a permanent fix is developed [6]. It's also crucial to document the reasoning behind decisions, especially when a vulnerability is categorized below the reporting threshold.

Risk Assessment and Mitigation Strategies

Risk Assessment Frameworks

After the initial vulnerability triage, detailed risk assessments take the lead in shaping your response plan. The FDA expects manufacturers to go beyond simply noting CVSS scores and instead map out the "exploit impact pathway" - showing how a cyber event could alter a device's behavior and, in turn, affect clinical outcomes [7].

Conducting this assessment requires teamwork. A cybersecurity technical lead analyzes exploitability and attack surfaces, while a clinical safety lead evaluates how a compromised device might impact patient safety. Ran Chen, a Global MedTech Expert, emphasizes the importance of this collaboration:

"A purely technical decision to isolate devices without clinical input can create greater patient safety risk than the cyber incident itself." [7]

The table below highlights how the criticality of a device should influence your response strategy:

Device Type Active Exploitation Response Suspected Exploitation Response
Life-sustaining (e.g., ventilator) Selective isolation; avoid powering off; implement clinical workarounds Enhanced monitoring; prepare for selective isolation
Life-supporting (e.g., infusion pump) Network isolation if standalone mode is safe; otherwise selective isolation Selective isolation; enhanced logging
Diagnostic (e.g., imaging system) Full network disconnection; switch to backup if available Selective isolation with monitoring
Administrative (e.g., billing) Full network disconnection; rebuild from backup Enhanced monitoring

Once risks are assessed, the next step is to determine the appropriate mitigation strategy.

Mitigation Decision-Making

Using the established risk profiles, manufacturers can select a mitigation approach. The FDA identifies four mitigation categories, each with unique regulatory requirements [6]:

  • Category A: Like-for-like library updates, such as patching OpenSSL without changing device behavior. These usually don’t require a new 510(k) submission.
  • Category B: Implementing compensating controls, like network segmentation or firewall rules, when direct patching isn’t an option.
  • Category C: Adjusting the security architecture, such as replacing cryptographic algorithms. This often triggers a new 510(k) assessment.
  • Category D: Disabling or modifying a device function to eliminate an attack vector entirely. This is the most disruptive choice and almost always requires a new submission.

Ran Chen offers critical insight here:

"The regulatory question is never whether to patch. The question is: what regulatory pathway does this specific patch require, how fast must it deploy, and what documentation must accompany it?" [6]

To avoid delays during a critical exploit window, it’s wise to pre-agree on protocols with your Notified Body regarding cybersecurity patches [6].

Documenting Risk Assessment Outcomes

Detailed documentation is your strongest defense during an FDA inspection. For each vulnerability, record its clinical impact, the mitigation strategy chosen, and the residual risk [2].

If you address a vulnerability that’s below the mandatory reporting threshold, document the rationale for your decision. This ensures you’re prepared if the FDA raises questions later [2]. As Blue Goat Cyber aptly points out:

"A postmarket surveillance security program is only as defensible as its records." [2]

It’s also crucial to differentiate between routine updates, which don’t require 806 reporting, and risk-reduction corrections, which must be reported within 10 working days [2]. Misclassifying these could lead to enforcement actions or unnecessary regulatory hurdles. Using structured templates to track details like device ID, exploit pathway, and residual risk can simplify this process during incidents [7].

An integrated risk management tool, such as Censinet RiskOps™, can further streamline documentation and ensure your risk assessments and mitigation efforts align with FDA postmarket cybersecurity requirements.

Remediation, Disclosure, and Stakeholder Communication

Executing Remediation Plans

Once continuous monitoring and risk assessments are in place, the next step is deploying fixes while ensuring the device's clinical performance remains intact. Unlike regular software updates, medical device patches require a formal design verification and validation process. This includes regression testing to confirm the patch doesn't interfere with the device's critical clinical functions.

To streamline this process, it's a good idea to establish a dedicated Sustaining Engineering Group. This team can focus on validating third-party patches without disrupting ongoing product development efforts.

Here’s a breakdown of the four key phases involved in a solid remediation program:

Remediation Phase Key Activities Regulatory Context
Intake & Triage Secure intake channel, execute CVD policy, initial severity scoring Section 524B(b)
Validation Regression testing, analyze clinical performance impact, documentation Quality System Regulation (QSR)
Reporting Determine if correction could prevent serious harm; file within 10 working days if required 21 CFR Part 806
Communication Deploy patches, notify healthcare delivery organizations (HDOs)/patients, update device labeling Section 502(f) (Misbranding)

In cases where an immediate patch isn't feasible, healthcare facilities should be provided with interim measures to mitigate risks until a permanent solution is ready.

Once remediation is complete, having a strong vulnerability disclosure process in place ensures transparency and fosters effective collaboration.

Coordinated Vulnerability Disclosure

The FDA expects manufacturers to have a Coordinated Vulnerability Disclosure (CVD) policy, as outlined under Section 524B for cyber devices [1]. This policy demonstrates to security researchers and healthcare partners that vulnerabilities are handled responsibly and transparently.

At a minimum, a compliant CVD policy should include:

  • A secure intake channel, such as a dedicated security email or web form.
  • A defined timeframe to acknowledge reports.
  • Severity-based response windows.

Aligning your CVD policy with established frameworks like those from CERT/CC and FIRST can enhance credibility. When vulnerabilities affect multiple products or involve third-party components, manufacturers must collaborate with all impacted vendors. Addressing such issues in isolation can leave exposure gaps across the ecosystem, making cross-vendor coordination a critical step.

Once vulnerabilities are disclosed, timely and clear communication becomes essential to ensure safety for patients and healthcare providers.

Communication with Healthcare Providers and Patients

Communication needs to follow a structured sequence: internal triage, immediate notification to healthcare facilities with specific remediation steps, and alerts to patients or providers only when the clinical risk warrants it [2]. Skipping steps or rushing the process can cause confusion at critical moments.

The clarity of your messaging is just as important as its timing. Christian Espinosa, Founder & CEO of Blue Goat Cyber, emphasizes this point:

"Vague advisories that don't identify affected product versions, don't include a clinical risk assessment, and don't provide specific remediation steps aren't acceptable." [2]

For patient communications, the message should be accessible, mobile-friendly, and written in plain language to cater to a diverse audience [8]. Whether addressing hospital biomedical teams or individual patients, advisories must clearly outline the vulnerability's risks, the benefits of continuing device use, and any uncertainties about the exploit. This level of transparency fosters trust, ensures safe device use during the remediation process, and reinforces the commitment to safety throughout the device's lifecycle.

Lifecycle Governance and Quality Systems Integration

Manufacturers must integrate cybersecurity controls into every phase of the product lifecycle, building on their risk assessment and remediation processes.

Documentation and Compliance Requirements

Effective postmarket cybersecurity isn't confined to engineering - it requires thorough documentation. The FDA mandates manufacturers to maintain detailed records that demonstrate ongoing oversight of device security.

Here are the key documentation categories and their requirements:

Documentation Category Key Records Required Regulatory Reference
Vulnerability Management Monitoring logs (e.g., NVD, ICS-CERT), triage records, CVSS scoring rationale Section 524B, 21 CFR 820.100
Software Inventory Updated SBOM (commercial, OSS, OTS components), version history Section 524B(b)
Remediation & Patching Design verification and validation reports, regression testing results, patch rationale 21 CFR 820.30(g), 21 CFR 820.200
External Communication Published CVD policy, intake logs, customer advisories, labeling updates ISO/IEC 29147, 21 CFR 806
Incident Reporting MDR submissions, Part 806 correction reports, clinical impact assessments 21 CFR 803, 21 CFR 806

One common oversight is failing to document vulnerabilities that don't meet FDA reporting thresholds. Under 21 CFR Part 806, manufacturers must report fixes within 10 working days if they prevent serious injury or death. For vulnerabilities below this threshold, documenting the clinical rationale behind the decision not to report is still critical. This not only helps during audits but also shows a proactive approach to oversight.

The Software Bill of Materials (SBOM) is vital for lifecycle governance. Christian Espinosa, Founder & CEO of Blue Goat Cyber, emphasizes its importance:

"An SBOM that reflects a build from two years ago is functionally useless for vulnerability monitoring because you can't match NVD advisories against components you haven't tracked accurately." [2]

To stay ahead, ensure your SBOM is updated with every change - whether you're adding components, updating versions, or removing dependencies. This practice supports regulatory compliance and strengthens your overall quality system. It also helps mitigate broader enterprise risks that can impact clinical and operational stability.

Integrating Cybersecurity into Quality Systems

Starting February 2, 2026, the FDA's QMSR will align with ISO 13485:2016, embedding cybersecurity into quality systems. This shift recognizes cybersecurity as an integral part of quality management, not just a technical concern.

In practical terms, cybersecurity issues must tie directly into your existing QMS processes. Ran Chen, a Global MedTech Expert, explains:

"If your threat model cannot be traced to Clause 7.3 design controls, your cybersecurity framework is structurally outside the quality system." [3]

Traceability to ISO 13485 Clause 7.3 (Design Controls) is non-negotiable. Additionally, when vulnerabilities stem from systemic issues like software development or supplier management, they should trigger the Corrective and Preventive Action (CAPA) process under Clause 8.5. All postmarket findings must also update the ISO 14971 risk management file, ensuring risk analyses reflect new hazards and residual risks after mitigation [6].

The FDA Compliance Program Manual #7382.850 now provides a clear framework for assessing cybersecurity during routine QMS inspections. This underscores the importance of integrating cybersecurity into your quality system [3].

Using Postmarket Findings to Improve Future Designs

Postmarket data - including trends in vulnerabilities and SBOM updates - can guide safer future designs.

The FDA advises:

"Using SPDF processes during device design may prevent the need to re-engineer the device when connectivity-based features are added after marketing and distribution." [10]

A Secure Product Development Framework (SPDF) connects postmarket insights to design decisions. For instance, if a recurring vulnerability is linked to a specific third-party component, or if a threat model exposes weaknesses in network handling, these findings should inform component selection and design validation efforts under ISO 13485 Clause 7.3.7.

This feedback loop is critical for continuous improvement. After addressing a postmarket vulnerability, conduct a review to update your cybersecurity risk management plan and identify design changes that could prevent similar issues. Over time, this process reduces vulnerabilities across your products and demonstrates to FDA inspectors that your quality system is both effective and evolving.

Conclusion and Key Takeaways

Christian Espinosa, Founder & CEO of Blue Goat Cyber, reminds us that "FDA clearance is the beginning of your cybersecurity obligations, not the finish line" [2]. This means manufacturers must stay vigilant - monitoring threats, assessing risks with patient safety in mind, addressing vulnerabilities methodically, and applying these lessons to future product designs.

Naomi Schwartz, VP of Regulatory Strategy at Medcrypt, further emphasizes the shift in approach:

"The rules of the game have changed. The landscape now is to design controls in, period. The FDA's cybersecurity authority is no longer based solely on risk assessments. It's based on statute, and statute says you must prove secure by design." [11]

The stakes are high. Data from mid-2020 through 2021 reveals that 82% of healthcare systems experienced a cyber incident, with 34% involving ransomware [7]. These events directly threaten clinical operations and patient safety, underscoring the critical need for proactive measures.

To address these challenges, manufacturers should focus on:

  • Maintaining an up-to-date SBOM (Software Bill of Materials): Regularly verify your version-pinned SBOM against the latest data from the NVD (National Vulnerability Database) and KEV (Known Exploited Vulnerabilities).
  • Establishing a Coordinated Vulnerability Disclosure (CVD) policy: Include clear response timelines and consider joining organizations like the Health Information Sharing and Analysis Center (H-ISAC), which the FDA views as essential for managing postmarket cybersecurity threats [9].
  • Incorporating cybersecurity findings into your QMS (Quality Management System): Use tools like design controls, CAPA (Corrective and Preventive Actions), and updates aligned with ISO 14971 to strengthen your processes.

FAQs

Which devices does the FDA consider “cyber devices” under Section 524B?

Under Section 524B of the FD&C Act, the FDA identifies a cyber device as any medical device that meets these three conditions:

  • It contains software that has been validated, installed, or authorized by the device sponsor.
  • It has the capability to connect to the internet or other networks through technologies like Wi-Fi, cellular, Bluetooth, radiofrequency, or physical ports such as USB and ethernet.
  • It incorporates technological elements that may be exposed to cybersecurity risks.

How do I know if a vulnerability requires FDA reporting under 21 CFR Part 806?

Under 21 CFR Part 806, manufacturers are required to report cybersecurity corrections and removals when they address a health risk. Routine updates or patches, which are often seen as improvements to the device, generally do not require reporting. However, if a vulnerability creates an uncontrolled risk to patient safety - such as impairing device functionality in a way that could result in death or serious injury - reporting becomes mandatory.

What should a minimum compliant SBOM and CVD policy include?

A compliant Software Bill of Materials (SBOM) needs to be machine-readable using formats like CycloneDX or SPDX. It must include seven key elements as outlined by NTIA:

  • Supplier name
  • Component name
  • Version string
  • Unique identifier
  • Dependency relationship
  • SBOM author
  • Timestamp

Additionally, it should provide details on support levels, end-of-support dates, and a vulnerability assessment that maps components to known CVEs or entries in CISA's Known Exploited Vulnerabilities catalog.

For a compliant Coordinated Vulnerability Disclosure (CVD) policy, organizations must establish:

  • A public reporting channel (e.g., email or security.txt)
  • A defined response SLA
  • Postmarket monitoring practices
  • A threat triage process
  • A way to notify customers about vulnerabilities and available patches

Tools like Censinet RiskOps™ simplify these processes, making it easier for healthcare organizations and vendors to manage compliance effectively.

Related Blog Posts